

TriNetX EMEA Report

ACCESS THE WORLD'S LARGEST SOURCE
OF REAL-WORLD PATIENT DATA FROM
EUROPE & THE MIDDLE EAST



Access real-world European & Middle Eastern patient data

Largest source of robust and continuously refreshed de-identified European and Middle Eastern clinical data.



Conduct region-specific studies compliant with local privacy regulations

Identify sites in the EMEA region that have eligible patients based on real data. Understand inclusion/ exclusion criteria and the impact on protocol design and feasibility.



Gain a path to real patients in the EMEA region

Have a path back to the identity of the patient if the healthcare organization decides to participate in your trial.

The TriNetX acquisition of Custodix and its InSite platform has resulted in the largest source of EMEA patient data in the world. A TriNetX EMEA Report combines EU data from InSite with EMEA data in the TriNetX platform. Researchers now have visibility to an expansive European and Middle Eastern patient population for protocol design and feasibility, site selection, and patient identification for recruitment.

The TriNetX EMEA Report provides access to a robust, continuously refreshed data source of de-identified EMR data of more than 16 million patient lives from 36 healthcare organizations across 12 countries.

Generating an EMEA Report

Using the TriNetX self-service user interface and best practice guidelines for querying EMEA data, you define the specific disease and population parameters of your query. Through the TriNetX platform, you submit your request and the TriNetX clinical sciences team generates the report which details the countries that have patients for the exact population you seek.


GDPR Compliant

All access to data through TriNetX EMEA Reports is de-identified and GDPR compliant. Because of the extra security and governance required for access to European healthcare data, patient counts are provided by country only. Once individual healthcare organizations share mutual interest in your study and provide consent, you can obtain patient counts by healthcare organization.

Key Features of the TriNetX EMEA Report

Site List & Patient Location

Every report includes a map and table detailing the healthcare organizations and number of patients in each country or region that meet the query criteria.



Criteria Analysis for Protocol Feasibility

The patient funnel provides insights into feasibility by outlining which I/E criteria are most limiting.

Analyze Criteria	Patients	HCOs
Network	74,518,930	43
Base Population	393,620 (-99%)	57
Population ≥ 18 years, Any sex	353,880 (-10%)	57
Event 3A This event occurred since 1 year ago. MUST HAVE: N29 Urinary tract infection, site not specified	101,480 (-71%)	54
Event 3B Any instance of Event 3B occurred at least 1 Day after any instance of Event 3A. MUST HAVE: N29 Urinary tract infection, site not specified	101,240 (0%)	54
Event 2A This event occurred since 7 days ago. CANNOT HAVE: AM000ANTIMICROBIALS (Any route)	101,240	54
Total	101,240 Patients	54 HCOs

These terms were selected in base population

MUST HAVE

Event 1A This event occurred since 1 year ago

N29.0 Urinary tract infection, site not specified

Integrated with TriNetX Trial Connect

Directly engage the right contacts at the right healthcare organizations quickly and easily, and centrally monitor site acceptances, declines, and pending responses.

Trial Details	All Sent	Pending	Interested	Not Interested
	2	2	0	0

Sample Query	Study Status	Therapeutic Area	Indication	Sent On
	Study Feasibility	Pulmonology	Test	Nov 07, 2018 3 months ago

Response Date	Status	HCO Name	Number of Patients	Additional Information
	Pending	Healthcare Organization D	110	
	Pending	Healthcare Organization B	540	

Query Execution Summary

The query summary includes specifics on how the analysis was conducted, including how the patient cohort was defined, how and what criteria was grouped into events, and what data types were available.

MUST Have	CANNOT Have
E11 Type 2 diabetes mellitus AND B0009 Insulin lipase Any route 1,379,670	C0702 Loop diuretics Any route 3,127,790
A0023 Hemoglobin a1c/hemoglobin total in blood ≥ 4 % , most recent value 7,333,110	

Event 1A

E08 Diabetes mellitus due to underlying condition	412,140
OR	
E09 Drug or chemical induced diabetes mellitus	359,130
OR	
E10 Type 1 diabetes mellitus	781,350
OR	
E12 Other specified diabetes mellitus	493,660

Event 2A

Z150.5 Body mass index ≥ 40 kg/m2, most recent value	23,775,100
OR	
Z68.4 Body mass index (BMI) 40 or greater, adult	926,230

About TriNetX, Inc.

TriNetX is the global health research network that revolutionizes clinical research and enables discoveries through the generation of real-world evidence. The HIPAA and GDPR compliant TriNetX platform combines real time access to longitudinal clinical data with state-of-the-art analytics to answer complex research questions at the speed of thought. For more information, visit TriNetX at www.trinetx.com or follow @TriNetX on Twitter.